Overview of the New Variant
As of May 2025, the emergence of a new COVID-19 variant, NB.1.8.1, is making headlines around the globe. This variant, a subvariant of the JN.1 lineage related to Omicron, has been associated with rising case numbers in several countries, including the United States, where it has recently been identified through airport screening protocols.
Characteristics of NB.1.8.1
Identified first in China, NB.1.8.1 is reported to have quickly become the dominant strain in the region, contributing to a significant uptick in COVID-19 infections. Its detection has extended to various parts of Asia, such as Singapore and Hong Kong, as well as to the U.S., highlighting the variant's rapid spread.
The World Health Organization (WHO) classified NB.1.8.1 as a SARS-CoV-2 variant under monitoring due to its increasing prevalence. Research indicates that the earliest sample was collected on January 22, 2025, and as of May 23, 2025, it was officially designated a variant under monitoring.
Symptoms and Transmissibility
The symptoms associated with NB.1.8.1 largely mirror those of previous Omicron variants, which include:
- Sore throat
- Fatigue
- Mild cough
- Fever
- Muscle aches
- Congestion
Some individuals have reported experiencing low-grade hyperthermia — a condition characterized by elevated body temperature resulting from thermoregulation issues, rather than traditional fever. Other notable symptoms involve headaches, gastrointestinal discomfort, and changes in appetite.
Preliminary findings suggest that NB.1.8.1 has a higher transmissibility rate compared to earlier variants. This is likely due to its improved ability to bind to human cells, which could facilitate an increase in infections. The variant has already been recognized in travelers at major U.S. airports located in California, Washington, Virginia, and New York.
Current Situation and Response
Despite the increase in reported cases and hospitalizations where NB.1.8.1 is prevalent, WHO data does not currently indicate that this variant causes more severe illness than its predecessors. Notably, several countries are experiencing a mild resurgence in COVID-19 cases, primarily linked to new Omicron subvariants like JN.1.
Dr. Divya K S, an infectious disease consultant, notes that periodic surges in infections are common as the virus transitions to an endemic phase. Factors contributing to these fluctuations include waning immunity, lower vaccination rates, and increased international travel. Most cases reported so far display mild symptoms, but vigilance is particularly necessary for vulnerable populations.
Protective Measures Advised
To safeguard health during this period, authorities recommend:
- Staying up to date with COVID-19 vaccinations and booster shots.
- Wearing masks in crowded or enclosed spaces.
- Practicing good hand hygiene.
- Monitoring symptoms and getting tested when feeling unwell.
- Following local health guidelines and advisories.
Global Reports and Surveillance
In recent updates, France reported its first four cases of the NB.1.8.1 variant, highlighting the variant's presence not only in Asia but also in Europe. Additional cases have been confirmed in Germany, Ireland, the Netherlands, Spain, and Sweden, confirming the variant's expanding footprint.
Although strong binding to human cells has been indicated, early studies suggest that NB.1.8.1 does not significantly evade immunity generated by vaccines or past infections. Health officials are urging the general public to remain cautious and adhere to ongoing public health recommendations as tracking of this variant continues.
Bias Analysis
Key Questions About This Article
